A new collaboration studying the impact of FXR function on HBV replications

ENYO Pharma is pleased to announce the initiation of a collaboration with the group of Professor Patrice Andr√© (Inserm U1111, Lyon, France) to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). In addition to identifying opportunities for new anti-HBV therapeutics, this collaboration will strengthen understanding of the mode of action of EYP001, ENYO’s lead compound. EYP001 is a highly selective FXR modulator that reduces the HBV cccDNA reservoir, blocks its transcription and the deleterious expression of viral proteins. A Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and single dose escalation has been completed.

Read next in 'Latest news'